Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Atlas acquisition of De La Rue gets regulatory OK in Malta

(Sharecast News) - De La Rue announced on Thursday that a key regulatory condition to its recommended acquisition by ACR Bidco, a company controlled by funds advised by Atlas Holdings, had been satisfied following clearance from Malta's National Foreign Direct Investment Screening Office. The London-listed security printing specialist said the clearance under Malta's National Foreign Direct Investment Screening Office Act removed one of the final regulatory obstacles to the all-cash takeover, which was first announced in April and was set to be effected by way of a court-sanctioned scheme of arrangement.

It followed earlier approvals, including shareholder consent obtained on 3 June and confirmation on 11 June from the UK Secretary of State that no further action would be taken under the National Security and Investment Act.

With the Maltese condition now met, De La Rue said the scheme remained subject to a small number of remaining conditions, including court approval at the sanction hearing scheduled for 30 June.

If approved, the scheme was expected to become effective on 2 July.

Applications had already been made to the Financial Conduct Authority and the London Stock Exchange to cancel the admission of De La Rue's shares to trading on the Main Market.

The cancellation was expected to take effect the day after the scheme became effective.

Under the terms of the agreement, Atlas Holdings would acquire all issued and to-be-issued shares of De La Rue.

At 1113 BST, shares in De La Rue were up 0.19% at 129.25p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.